1. Scrip
  2. >>New Products

AstraZeneca/Daiichi's Enhertu Expansion Strategy Progresses With New Approval

 
• By Jessica Merrill

Enhertu secured US FDA approval as a second-line treatment in HER2-positive breast cancer, where it is poised to become the new standard of care.

growth expansion
Enhertu is poised for growth • Source: Shutterstock

AstraZeneca PLC and Daiichi Sankyo Co., Ltd.'s Enhertu (fam-trastuzumab deruxtecan) was approved by the US Food and Drug Administration for the treatment of second-line HER2-positive breast cancer, expanding its use to an earlier line of treatment, where it is poised to become the new standard of care.

The latest approval is part of a step-wise expansion strategy for Enhertu that is expected to build the cancer drug...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from New Products

More from Scrip

China’s Biotechs Were The Small-Cap Rising Stars In H1 2025

 
• By Andrew McConaghie

The list of small-cap companies with the fastest-rising share prices so far this year is dominated by Chinese companies, underscoring their growing contribution to the global biopharma ecosystem.

In Brief: Soleno To Raise $200m To Boost Vykat XR Launch

 
• By Manas Mishra

Soleno Therapeutics will raise about $200m gross proceeds from an offering of 2.35m of its common stock to fund the commercialization of Vykat XR, which became the first drug for Prader-Willi syndrome to gain US approval on March 26.

Glenmark Chief On IGI’s Landmark Trispecific Deal: Strong Data Excited AbbVie

 
• By Anju Ghangurde

Glenmark’s managing director talks about IGI’s billion dollar-plus deal with AbbVie, ISB-2001’s striking data, the BEAT platform, other "exciting" pipeline assets and the "blood, sweat and tears" to get to this stage.